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AUTHOR’S NOTE
The Baker Institute Drug Policy Program 
began in 2001. After an inaugural 
conference in April 2002, the first topic I 
chose to write about was needle exchange 
programs, a proven way to reduce the 
transmission of blood-borne diseases such 
as HIV/AIDS and hepatitis among injecting 
drug users. I chose needle exchange for 
a simple reason: I thought it made sense 
to advocate for a nonpartisan policy that 
would not only reduce suffering and save 
lives and money but, once its advantages 
were clearly delineated, would be embraced 
and enacted into law by Texas legislators.  
I was mistaken.
 In this issue brief, I will summarize the 
scientific and fiscal evidence supporting 
needle exchange, trace recent developments, 
and recommend a framework for dealing 
with these and other aspects of drug use and 
abuse. The early and concluding sections are 
identical or quite similar to portions of my 
earlier writing on this topic.1
Terminology
In recent years, needle exchange programs 
(NEPs) began to be called Syringe Exchange 
Programs (SEPs), properly reflecting the 
fact that HIV and hepatitis viruses could 
live not only on the needle, but also within 
the syringe itself. Then, as established SEPs 
added distribution of condoms, offered 
information about avoiding disease, provided 
some primary health care and counseling, 
and connected people to treatment and 
recovery programs, they increasingly have 
come to be called Syringe Services Programs 
(SSPs), reflecting the wider scope of their 
offerings. Similarly, injecting drug users 
(IDUs) are increasingly referred to as PWID 
(People Who Inject Drugs), in recognition of 
the fact that injecting drug use is not the 
only relevant facet of their personhood. In 
this publication, I will use the newer labels.
BACKGROUND
A contaminated needle is an extremely 
efficient transmitter of blood-borne disease, 
and the virus can live on a needle or within 
a syringe for as long as four days. Further, 
since the Centers for Disease Control and 
Prevention (CDC) estimates that at least a 
quarter of the people infected with HIV were 
unaware of it until they were diagnosed, 
and since the rapidity of infection with 
hepatitis C (HCV) results in an even greater 
percentage of unsuspecting carriers, needle 
users are key agents in the spread of these 
deadly epidemics.
 The illegal drugs most commonly 
injected are heroin, cocaine, and 
methamphetamines, although each of 
these can be taken by other means, such 
as snorting, smoking, or ingesting orally. 
Prescription drugs can also be crushed into 
powder and made injectable. Using these 
drugs, particularly in the corrupted state 
in which they typically reach the retail 
market, is risky business. This inherent 
risk is substantially increased when users 
share needles contaminated by blood-
borne diseases, most notably HIV/AIDS and 
hepatitis A, B, and C. 
A contaminated needle 
is an extremely efficient 
transmitter of blood-
borne disease, and 
the virus can live on 
a needle or within a 
syringe for as long as 
four days.
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Europe, Central Asia, and Australia and New 
Zealand. In some locales, sterile syringes 
can be exchanged at pharmacies, police 
stations, and even from specially designed 
vending machines. Even in Iran, the hyper-
conservative ruling mullahs have approved 
of syringe exchange as a way to fight an HIV/
AIDS epidemic spread mainly by drug users.
 Persuaded by scientific consensus and 
international examples, numerous U.S. cities 
have established SEPs that produce positive 
results. Most are in urban areas. Many are 
understaffed, underfunded, and unable 
to offer anything like the services that 
are needed. But when run well, they can 
dramatically reduce the spread of diseases. 
Two notable long-standing examples 
operate in Baltimore and New York City. 
Baltimore
After the Baltimore City Needle Exchange, 
established in 1992, had been in operation 
for six years, the incidence of HIV in that 
city dropped by 35 percent overall and 70 
percent among the approximately 10,000 
participants in the program. By 2012, the 
percentage contracting HIV through injection 
had dropped from 53 percent to 12 percent.5 
The Baltimore program, whose several vans 
provide clean needles at 16 locations, is such 
a standard part of the city's public health 
services that when snow halts its regular 
rounds, the news is carried on radio, TV, and 
Facebook right along with school closings.6 
New York City
In New York City, the HIV rate among 
PWID climbed to 54 percent before the 
introduction of SSPs in the early 1990s. 
Thanks to SSPs and other prevention 
measures, it had fallen to 13 percent by 2001 
and is now down to less than 1 percent. 
Epidemiologist Don Des Jarlais, director of 
research at New York’s Mount Sinai Beth 
Israel medical center and a leading expert 
on syringe exchange, said, “We appear to be 
very close to eliminating injecting-related 
transmission in a city with over 150,000 
injecting drug users.”7
The lifetime cost 
of treating (HIV or 
hepatitis C) can easily 
exceed $300,000, 
much of which is paid 
by Medicaid, Medicare, 
local hospital districts, 
the U.S. Department of 
Veterans Affairs, and 
other public funds.
 The actual result is stunning. Informed 
estimates of the number of PWID range 
from a quite conservative 1 million to a 
more common figure of approximately 1.2 
million. By the end of 2002, according to the 
CDC, 32 percent of people living with AIDS 
in the United States were PWID, as were 28 
percent of new diagnoses in that year.2
 By 2015, the proportion of new HIV/
AIDS diagnoses had dropped to 9 percent 
and the CDC credited SSPs with playing a 
significant role in that decline.3 Hepatitis C, 
the most dangerous variant of that disease, 
is also rampant among PWID in the United 
States; surveys consistently find that 50 to 
80 percent contract the virus within the first 
year of needle use and that it is found in the 
blood of 70 to 90 percent of all adult PWID.
 The lifetime cost of treating either of 
these diseases can easily exceed $300,000, 
much of which is paid by Medicaid, 
Medicare, local hospital districts, the U.S. 
Department of Veterans Affairs, and other 
public funds.4 Thus, every case of HIV/
AIDS or HCV prevented by syringe exchange 
carries an extraordinary cost benefit. In 
addition, SEPs take millions of potentially 
contaminated needles out of circulation 
instead of leaving them to be passed around 
or left in parks or public restrooms, where 
they could injure or infect children and 
others, including health workers and police 
who might receive needle-stick injuries in 
their contact with addicts. 
THE SCIENCE IS CLEAR
At least eight major studies, conducted 
by such organizations as the National 
Academy of Sciences, the CDC, the American 
Medical Association, and the World Health 
Organization, have unanimously concluded 
that access to clean needles dramatically 
reduces the incidence of blood-borne 
diseases and neither encourages people to 
start injecting drugs nor increases drug use 
by those who are already users. In addition, 
they serve as a bridge to treatment for a 
substantial minority of participants. 
 Syringe exchange is now an accepted 
part of public health programs in almost 
all countries of Western and Eastern 
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THE CURRENT SITUATION 
While the widespread attention currently 
given to opioid abuse stresses that addiction 
can happen anywhere, its incidence is hardly 
random. The map in Figure 1, prepared by 
the CDC in October 2016, shows (in pink) 
U.S. counties deemed to be particularly 
“vulnerable to rapid spread of HIV and 
hepatitis C infection among people who 
inject drugs.” Of 220 such counties in the 
nation, the most by far are concentrated in 
central Appalachia (Tennessee, Kentucky, 
West Virginia, southern Ohio, and Indiana). 
The green dots represent SSPs, none of 
which existed in this cluster of states 
in 2014. In addition to having four-fold 
increases in hepatitis C  infections and 
comparable increases in HIV, these counties 
are also marked by “high unemployment 
and poverty, low educational attainment, 
and limited access to health care,” all factors 
known to contribute to drug abuse.8
 Typically, excess prescription of oral 
opioid painkillers such as oxymorphone 
(Opana), oxycodone (Oxycontin, a key 
ingredient in Percocet), hydrocodone (a 
primary ingredient in Lortab, Vicodin, et 
al.), and hydromorphone (Dilaudid) led to 
abuse and dependence, particularly among 
young (median age 32) white residents of 
rural communities and small towns. As their 
dependence increased and as reformulation of 
the drugs and restrictions on prescribing them 
made them harder to obtain, many users 
devised ways to crush pills into injectable 
form, which provided a quicker and more 
intense rush than ingesting them orally. Many 
turned to heroin, soon more readily available 
and cheaper, but also with no pharmaceutical 
FIGURE 1 — COUNTIES VULNERABLE TO HIV/HCV & LOCATIONS OF SYRINGE SERVICES PROGRAMS (2016)
SOURCE  Lauren Canary, Centers for Disease Control and Prevention, Division of Viral Hepatitis. Vulnerable counties data from Van Handel, M.M., et al; JAIDS, 
November 2016, 73(3); 323-331. Syringe services data from North American Syringe Exchange Network (www.nasen.org/directory).9
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 Pence’s concession was not complete. 
Instead of embracing the public health model 
of preventing disease before it spreads, 
he backed legislation that required county 
officials to wait until increases in HIV and HCV 
were sufficient to justify declaring a public 
health emergency, then submit a plan to the 
state for approval to set up SSPs, with a time 
limit of one year. The state also provided little 
or no funding to help counties set up their 
programs. As a result, by the end of 2016, for 
every one of the fewer than 10 counties with 
programs underway, two others had failed 
to get started.12 Bureaucratic tensions and 
apparent turf wars among state, county, and 
nonprofit entities have contributed further to 
uneven progress.
 The New England Journal of Medicine 
criticized Indiana’s reluctance to accept 
the reality that preventing the spread of 
blood-borne chronic diseases requires 
continuous access to sterile syringes.13 
Similarly, a spokesman for the Foundation 
for AIDS Research said, “We must give Gov. 
Pence credit for finally doing the right thing 
in the end,” but he called the state’s HIV 
outbreak “entirely preventable…Indiana 
taxpayers could have been saved millions 
of dollars for treating those affected by the 
HIV outbreak if effective prevention policies 
were already in place.”14
 In January 2017, Indiana Health 
Commissioner Jerome Adams pronounced 
SSPs to be a success, telling the Senate 
health committee that new cases of HIV had 
dropped from c. 22 per week at the 2015 
peak to no more than three.15
 Pence’s successor as governor, 
Republican Eric Holcomb, supported SSPs 
during his campaign, voiced strong support 
for existing programs after taking office 
(despite resistance from his attorney general), 
and pledged to give local communities more 
freedom to set up SSPs without having to go 
through the cumbersome process established 
in the previous administration. On February 
1, 2017, the Indiana House voted 72-26 in 
favor of just such a measure. “Locals can 
act quickly when they become aware of an 
outbreak,” the author of the bill said. “If they 
have to wait the situation can get out of 
control quickly.”16
label to indicate its strength. Eventually, in 
part because some dealers laced the heroin 
with fentanyl, an opioid estimated to be 20 
to 50 times stronger than heroin, overdoses 
increased, too often resulting in death. 
 In the absence of SSPs or other ways to 
obtain sterile syringes legally, PWID shared 
those they could obtain, sharing disease 
in the process. As the opioid epidemic 
progressed, each state has been forced to 
confront its stubborn resistance to syringe 
exchange and to make some accommodation 
to settled science. Two cases in particular, 
Indiana and Kentucky, have particular 
relevance for ongoing public policy.
Indiana
After several years of an average five 
new diagnoses of HIV per year in the 
southeastern part of Indiana, 169 new cases 
appeared by mid-June 2015 and more than 
20 new cases were being diagnosed every 
week. More than 80 percent of those also 
had HCV.10 The epicenter of the outbreak 
was Scott County, on the border with 
Kentucky, just north of Louisville. With 
no SSP, PWID had no legal way to obtain 
sterile syringes—possession of a needle 
without a prescription for medical use 
was a felony that carried a possible three-
year prison sentence. They also had little 
opportunity to learn whether they were 
infected after spending cuts and then-
Governor Mike Pence’s opposition closed the 
Planned Parenthood office that had been 
the only HIV testing center in the county. 
As a result, drug users spread the virus by 
sharing needles. According to the Kentucky 
Standard, a huge majority of cases reported 
in Scott County were traced back to a single 
infected individual.11
 Under pressure from public health 
officials in Indiana and elsewhere, and despite 
his opposition to SSPs, Governor Pence 
issued a temporary suspension of Indiana’s 
prohibition and allowed Scott County to set up 
a syringe exchange—for 30 days. Inevitably, 
as the epidemic did not wondrously disappear, 
that permission was extended to a year and 
then statewide, as other counties sought to 
avoid similar calamities.
At least eight major 
studies…have 
unanimously concluded 
that access to clean 
needles dramatically 
reduces the incidence 
of blood-borne diseases 
and neither encourages 
people to start injecting 
drugs nor increases drug 
use by those who are 
already users. 
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Kentucky
Pence’s example, however limited, may 
sway other governors and legislators who 
have been reluctant to accepts SSPs, but 
Kentucky’s experience will have a longer-
lasting positive impact.
 As Scott County’s proximity to Louisville 
and its similarity to many rural counties in 
Eastern Kentucky suggest, the Bluegrass 
State also shared similar drug and disease 
problems. At least 1,248 people died of drug 
overdose in 2015, a 17 percent increase 
from 2014.17 In addition to a significant HIV 
problem, Kentucky had the highest rate of 
new HCV infections in the nation—4.1 per 
100,000, nearly seven times higher than the 
national average of 0.6.18 
 In March 2015, just hours before the 
2015 session ended, the Kentucky General 
Assembly passed an emergency measure 
that levied harsh penalties against heroin 
dealers, increased the availability of 
naloxone, and included a Good Samaritan 
provision that protected people from 
prosecution when seeking help for a person 
who has overdosed. It also permitted 
health departments to establish needle 
exchange programs if local jurisdictions 
approve.19 Predictably, departments and 
local newspapers embraced the opportunity, 
but because the bill provided no funding 
for SSPs, getting them off the ground was 
a challenge. Except for the first four years 
of the Obama administration, Congress had 
banned federal funding for syringe exchange 
since 1988. If the opioid crisis had broken 
out in Massachusetts or Oregon, the chances 
of overturning the ban would have been 
small. Fortunately, Kentucky had Republican 
friends in high places. Under pressure from 
constituent communities faced with the 
reality of increasing drug use and rising rates 
of disease, Representative Harold Rogers, 
chairman of the U.S. House Appropriations 
Committee, and Senate Majority Leader 
Mitch McConnell successfully tucked 
removal of the ban into the 2016 omnibus 
spending bill.20 Under the terms of the 
bill, federal funds can be used to pay staff, 
rent office space, provide vans, and cover 
other costs—but not to provide syringes or 
needles,21 a provision apparently included 
to allow reluctant legislators to assure their 
constituents, “I did not have needles with 
‘those people.’” 
 Though warmly welcomed, the victory 
is not total. No additional funds were 
allocated for SSPs, so they must compete 
with other programs that depend on federal 
drug policy money, a slow process that will 
waste precious time in a situation where 
speed is crucial. An Oxford University 
study of a 1990s AIDS epidemic specifically 
identified SSPs as “the only measures 
that can target transmissions that happen 
within the first month.” Without such 
intervention,” one researcher observed, “the 
spread of HIV among drug-using populations 
is a public health time bomb.”22
 Other states in the region—Ohio, 
Virginia, West Virginia, Tennessee, and North 
Carolina—have stepped aboard the SSP 
van, as have Massachusetts, Connecticut, 
and Vermont. New Jersey already had 
privately funded pilot SSPs, but in August 
2016, Governor Chris Christie signed a bill 
that directed the health department to 
allocate $200,000 to programs that were 
running out of money to buy syringes.23 
And, surprising to some, the conservative 
Utah Legislature, faced with high rates of 
overdose deaths and hepatitis C infections, 
not only legalized SSPs but allowed other 
public and private organizations “to take 
used needles from anyone and provide them 
with new, sterile ones in return.”24
THE TEXAS SITUATION
In its latest count, the North American Syringe 
Exchange Network (NASEN) was aware of 
228 SSPs in 35 U.S. states, Washington, D.C., 
Puerto Rico, and the Indian Nations.25 Others 
are known to exist under the radar. Taking its 
familiar place on so many measures of public 
welfare, Texas ranks dead last in making it 
legally possible for PWID to have access to 
sterile syringes, although a tiny number of 
sub rosa efforts exist and some pharmacies 
will sell syringes to PWID.
 Needle exchange bills have been 
presented in every session of the Texas 
Legislature since the early 1990s, but 
were not taken seriously until 2005, when 
In New York City,  
the HIV rate among 
people who inject drugs 
(PWID) climbed to 54 
percent before the 
introduction of syringe 
service programs (SSPs) 
in the early 1990s. 
Thanks to [syringe 
exchange] and other 
prevention measures, 
it is now down to less 
than 1 percent.
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counties—Bexar, Dallas, El Paso, Harris, 
Nueces, Travis, and Webb counties—or a 
hospital district in those counties, passed 
the House County Affairs Committee 9-0 
and sailed through the House on a 92-37 
vote. Since 2009, Senate supporters have 
opted to wait for the House to pass its 
version of the bill rather than mount another 
pointless run. Given the changed make-
up of the Senate since the 2010 elections 
and Lt. Governor Dan Patrick’s long-
standing opposition to SEPs, it is not clear 
McClendon’s new bill would have passed the 
Senate. In any case, for reasons not entirely 
clear, Patrick’s office did not assign the bill 
to an appropriate committee until it was too 
late to get a hearing.
 Representative McClendon resigned from 
the Legislature in January 2016 because of 
illness. The effort to legalize SEPs during the 
2017 legislative session is being led by Dallas-
area Representative Toni Rose, author of HB 
3256, quite similar to McClendon’s bill. Given 
the 2015 vote, the House will likely approve 
this bill. Given Patrick’s past votes against 
syringe exchange and the failure to get a 
Senate hearing in 2015, optimism is modest. 
Even if the bill passed both houses, it might 
still face a veto from now-Governor Abbott, 
who in 2015 vetoed a “Good Samaritan” bill 
that had passed the Senate by 30-1 and the 
House by 140-4. That veto would have been 
overridden had the governor not waited until 
after the legislative session ended to render 
his verdict.27
HARM REDUCTION
Like many organizations concerned with 
problematic drug use and ineffective drug 
policy, the Baker Institute Drug Policy 
Program advocates an approach known 
as harm reduction, which includes the 
following key principles, presented below 
almost verbatim from a longer list on the 
Harm Reduction Coalition website.28
• It accepts that licit and illicit drug use, 
for better or worse, is part of our world 
and cannot be eliminated by prohibition 
or punishment. A drug-free America is a 
fantasy and zero tolerance is a failed policy. 
It is possible and preferable, however, 
Senator Jon Lindsay, a respected Republican 
from Houston, authored a bill that would 
have made it legal for private individuals 
and organizations to fund and operate SEPs, 
not costing the state a cent but potentially 
saving millions of dollars. The bill did not 
come to a vote in the Senate. 
 In 2007, a similar bill sponsored by 
conservative Republican senator and 
physician Robert Deuell passed in the Senate 
by a 23-8 vote but was blocked in the House 
by the chair of the Public Health Committee, 
who refused to allow a committee vote. 
But in a little-heralded action in the same 
session, the Texas Legislature approved a 
comprehensive health measure that included 
a one-paragraph amendment that gave Bexar 
County permission to establish a pilot SEP.26
 Bexar County’s district attorney at 
the time, however, recognized that the 
bill did not contain a clause exempting 
participants from possessing or distributing 
drug paraphernalia, which included syringes, 
and charged three program volunteers 
with a Class A misdemeanor, punishable by 
a $2,000 fine and up to a year in jail. The 
incident drew wide attention, most of it 
sympathetic to the volunteers and critical 
of the DA, but then-Attorney General Greg 
Abbott ruled that she had the legal right to 
exercise prosecutorial discretion and ignore 
the clear intent of the legislation. In the end, 
the volunteers did not go to jail, but the DA’s 
and Abbott’s decisions effectively shut down 
needle exchange in San Antonio for the 
last nine years, even though the enabling 
measure remains on the books and could be 
enacted in a favorable political climate and 
with cooperation from the current DA.
 In 2009, the Senate passed Deuell’s 
bill again with equally bipartisan (23-6) 
support. The House version, sponsored 
by Representative Ruth Jones McClendon, 
D-San Antonio, went forward on a 7-3 vote 
from the Public Health Committee and, 
championed by mostly Republican medical 
personnel, was expected to win on the 
House floor. Instead, it was orphaned when 
the legislative clock ran down on the 140th 
day. Similar fate met similar bills in the 
2011 and 2013 sessions, but Representative 
McClendon’s 2015 bill, which would 
have authorized pilot programs in seven 
Taking its familiar place 
on so many measures  
of public welfare,  
Texas ranks dead last in 
making it legally possible 
for PWID to have access 
to sterile syringes, 
although a tiny number 
of sub rosa efforts  
exist and some 
pharmacies will sell 
syringes to PWID.
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to minimize harmful effects rather than 
simply ignore or condemn them. 
• It acknowledges that some ways of using 
even dangerous drugs are clearly safer 
than others and calls for appropriate 
nonjudgmental, non-coercive provision 
of services and resources to people who 
use drugs and to the communities in 
which they live. 
• It affirms that drug users themselves can 
become important agents of reducing the 
harms of their use, sharing information, 
and supporting each other in strategies 
that meet the actual conditions of use.
Applied to syringe exchange, these 
principles have led to the development 
of an evolving set of “best practices,” 
including the following, excerpted from 
or based on a document prepared by the 
staff of the New York City Department of 
Health and Mental Hygiene and reflecting 
the consensus views of the nation’s leading 
syringe-exchange experts.29
• Maximize the number and variety of 
“access points” where PWID can obtain 
new and sterile syringes free of charge. 
• Where possible, provide or coordinate 
provision of other services: food and 
clothing distribution, ancillary medical 
care (disease screening, vaccinations, 
some primary care), social services  
(e.g., housing, legal aid, drug abuse 
treatment), and counseling (e.g., safer 
sex, overdose prevention).
• Adapt the service delivery environment 
to the particular life circumstances of 
participants (e.g., non-English speakers, 
youth, homeless, undocumented 
workers, sex workers, LGBPTQ, et al.) and 
deliver services in a supportive, non-
condemning and non-punitive matter.
• Provide as many syringes as PWID 
request at each transaction. Initially 
and still in many programs, programs 
have followed a one-to-one exchange 
requirement. Removing that requirement 
allows PWID to be sure they do not run 
out of sterile syringes in case they are 
unable to go to an SSP at the stated 
time. Existing evidence is strong that 
people who participate in SSPs are 
typically careful about returning their 
used syringes, both to avoid having 
the programs cancelled and also out of 
recognition that abandoned needles pose 
a danger to children and others.
• Promote and encourage “secondary 
syringe distribution” by permitting 
participants to distribute sterile syringes 
to people who for various reasons do not 
access the service directly. This can serve 
as a conduit for peer education when, for 
example, PWID who carry out secondary 
exchange provide safe injection information 
to those who are not accessing SSPs.
• Allow pharmacies to sell syringes 
without a prescription. Pharmaceutical 
associations favor syringe exchange, and 
the practice exists in some cities.
• Allow anonymous, confidential 
participation and minimize the data-
collection burden on programs and 
participants. The desire of legislators and 
other officials to confirm that the programs 
are successful is understandable, and 
satisfying that desire may be necessary to 
initiate such programs, but the science is 
unambiguously clear. Syringe exchange 
works to reduce the spread of blood-borne 
diseases without increasing drug use. 
Burdening program participants and staff 
with compiling records beyond the basics—
numbers of syringes distributed in a given 
period, numbers returned, and available 
data on HIV and hepatitis—is now a 
cumbersome, unnecessary burden on staff 
and a possible hindrance for participants.
CONCLUSION
No responsible person wants to encourage 
drug abuse. No fiscally prudent person wants 
to waste money simply to satisfy a sense 
of righteous indignation. No compassionate 
person wants to consign people unnecessarily 
to death or a living hell. Fortunately, providing 
people who inject drugs with access to sterile 
syringes allows us to be responsible, prudent, 
and compassionate—admirable criteria for 
good public policy.
 Syringe exchange has been a bipartisan 
effort in the Texas Legislature. We urge all 
Republicans, Democrats, and Independents 
Providing people 
who inject drugs 
with access to sterile 
syringes allows us to be 
responsible, prudent, 
and compassionate—
admirable criteria for 
good public policy.
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who believe in scientific evidence, public 
health, and compassion for others to contact 
their legislators, Lt. Governor Patrick, and 
Governor Abbott, and ask them to support 
bills establishing the legality of syringe 
exchange. It’s the right thing to do. 
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